Staging ::: VER CORREOS
Acceder

Seguimiento de Moderna (MRNA)

60 respuestas
Seguimiento de Moderna (MRNA)
5 suscriptores
Seguimiento de Moderna (MRNA)
Página
3 / 5
#31

Re: Seguimiento de Moderna (MRNA)

+9%
#32

Re: Seguimiento de Moderna (MRNA)

+9%. Como un cohete


+12%
#33

Re: Seguimiento de Moderna (MRNA)

comienza fase 3, sube un 10%
#34

Re: Seguimiento de Moderna (MRNA)

Increible que los directivos tengan tan poca confianza y estén vendiendo acciones desde hace varias semanas

#35

Re: Seguimiento de Moderna (MRNA)

Les ha tocado la loteria, y quedran cobrar el boleto antes de que caduque.
Saludos
#37

Re: Seguimiento de Moderna (MRNA)

Alguien sabe responderme a esta pregunta fundamental... porque el ingreso anual 2019 60M es menor que el beneficio neto 2019 500M.
Razón???
#38

Re: Seguimiento de Moderna (MRNA)

Análisis Moderna Inc (MRNA)
 

Perfil de la Empresa:
MODERNA, INC. se dedica a los medicamentos transformativos basados en el ácido ribonucleico mensajero (ARNm). Ha creado una plataforma para mejorar las propiedades farmacéuticas subyacentes de nuestros medicamentos de ARNm. Su plataforma consta de tres áreas: Tecnologías de ARNm, Tecnologías de entrega y Procesos de fabricación. Se busca la ciencia del ARNm para minimizar la activación indeseable del sistema inmunológico por el ARNm y maximizar la potencia del ARNm una vez en las células diana. Ha avanzado en paralelo un desarrollo diverso de 21 programas, de los cuales 10 han ingresado en estudios clínicos y otros tres tienen IND abiertos. Sus programas terapéuticos y de desarrollo de vacunas abarcan enfermedades infecciosas, oncología, enfermedades cardiovasculares y enfermedades genéticas raras. Ha creado seis modalidades de vacunas profilácticas, vacunas contra el cáncer, inmuno-oncología intratumoral, terapias regenerativas localizadas, terapias de secreción sistémica y terapias intracelulares sistémicas.

Comentarios: Moderna Inc (MRNA), es alcista para largo plazo. En estos momentos, se encuentra realizando su pauta de continuidad. Si lo superara, podría tener un posible objetivo sobre los 100 dólares. El punto a vigilar para este trimestre serían los 50 dólares. Si los perdiera, indicaría debilidad.

Los datos fundamentales indican un PER negativo por los resultados. Tiene una deuda total del 2,3%. Su ratio de solvencia se sitúa en 17,3. Mi ratio potencial sale a 22,8, indicando crecimiento económico. Mi fuerza de tendencia sale +16%, indicando crecimiento alcista.

 
Conclusión: Atentos a la rotura de la pauta para tomar posiciones alcistas. Vigilar el punto importante.


 
Disclaimer de Contenido
Las inversiones en bolsa son de alto riesgo y se puede perder el capital que se vaya a invertir. El usuario debe tener el conocimiento suficiente del funcionamiento y del riesgo de los productos de inversión que vaya a utilizar. Las ideas o análisis no garantiza rentabilidades en las inversiones, ni tampoco garantiza la ausencia de pérdidas que el usuario realice.
#39

Re: Seguimiento de Moderna (MRNA)

Como lo veis?
#40

Comunicado de Moderna

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 30, 2020-- Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the primary efficacy analysis of the Phase 3 study of mRNA-1273 conducted on 196 cases confirms the high efficacy observed at the first interim analysis. The data analysis indicates a vaccine efficacy of 94.1%. Safety data continue to accrue and the study continues to be monitored by an independent, NIH-appointed Data Safety Monitoring Board (DSMB). The Company also announced that today, Moderna plans to request an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) and conditional approval from the European Medicines Agency (EMA). The Phase 3 study, known as the COVE study, enrolled more than 30,000 participants in the U.S. and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services.

The primary endpoint of the Phase 3 COVE study is based on the analysis of COVID-19 cases confirmed and adjudicated starting two weeks following the second dose of vaccine. Vaccine efficacy has been demonstrated at the first interim analysis with a total of 95 cases based on the pre-specified success criterion on efficacy. Today’s primary analysis was based on 196 cases, of which 185 cases of COVID-19 were observed in the placebo group versus 11 cases observed in the mRNA-1273 group, resulting in a point estimate of vaccine efficacy of 94.1%. A secondary endpoint analyzed severe cases of COVID-19 and included 30 severe cases (as defined in the study protocol) in this analysis. All 30 cases occurred in the placebo group and none in the mRNA-1273 vaccinated group. There was one COVID-19-related death in the study to date, which occurred in the placebo group.

Efficacy was consistent across age, race and ethnicity, and gender demographics. The 196 COVID-19 cases included 33 older adults (ages 65+) and 42 participants identifying as being from diverse communities (including 29 Hispanic or LatinX, 6 Black or African Americans, 4 Asian Americans and 3 multiracial participants).

The safety profile of the Phase 3 study of mRNA-1273 was previously described on November 16. A continuous review of safety data is ongoing and no new serious safety concerns have been identified by the Company. Based on prior analysis, the most common solicited adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.

The Company will submit data from the Phase 3 COVE study to a peer-reviewed publication.

“This positive primary analysis confirms the ability of our vaccine to prevent COVID-19 disease with 94.1% efficacy and importantly, the ability to prevent severe COVID-19 disease. We believe that our vaccine will provide a new and powerful tool that may change the course of this pandemic and help prevent severe disease, hospitalizations and death,” said Stéphane Bancel, Chief Executive Officer of Moderna. “I want to thank the thousands of participants in our Phase 1, Phase 2 and Phase 3 studies, as well as the staff at clinical trial sites who have been on the front lines of the fight against the virus. I would again like to thank our partners at NIH, NIAID, BARDA and Operation Warp Speed who have helped us advance the clinical development of mRNA-1273. Finally, I want to thank the Moderna team and our suppliers and partners for their tireless work on the research, development and manufacturing of our vaccine. We will file today for an Emergency Use Authorization from the FDA and continue forging ahead with the rolling reviews that have already been initiated with several regulatory agencies around the globe.”

Today, Moderna will submit for an EUA with the U.S. FDA and an application for Conditional Marketing Authorization (CMA) with the European Medicines Agency. The Company has already initiated the rolling review process with the EMA, Health Canada, SwissMedic, the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA), Ministry of Health in Israel, and Health Sciences Authority in Singapore and intends to seek Prequalification (PQ) and/or Emergency Use Listing (EUL) with the World Health Organization (WHO).

Additionally, Moderna announced that the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting to review the safety and efficacy data package for mRNA-1273 will likely be scheduled for Thursday, December 17. The Company expects that the U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) will make a recommendation on immunization priorities. The Company anticipates that the shipping of mRNA-1273 to designated distribution points throughout the U.S. will occur shortly after an Emergency Use Authorization is granted.

Moderna is working with the U.S. CDC, Operation Warp Speed and McKesson (NYSE: MCK), a COVID-19 vaccine distributor contracted by the U.S. government, as well as global stakeholders to be prepared for distribution of mRNA-1273, in the event that it receives an EUA and similar global authorizations and approvals. By the end of 2020, the Company expects to have approximately 20 million doses of mRNA-1273 available in the U.S. The Company remains on track to manufacture 500 million to 1 billion doses globally in 2021. On November 10, the American Medical Association (AMA) issued a Current Procedural Terminology (CPT) code to report vaccination with mRNA-1273 (code: 91301). Moderna recently announced further progress towards ensuring the distribution, storage and handling of the vaccine can be done using existing infrastructure.


About the Phase 3 COVE Study

The Phase 3 COVE trial is a randomized, 1:1 placebo-controlled study testing mRNA-1273 at the 100 µg dose level in 30,000 participants in the U.S., ages 18 and older. The primary endpoint is the prevention of symptomatic COVID-19 disease. Key secondary endpoints include prevention of severe COVID-19 disease and prevention of infection by SARS-CoV-2. The trial will continue to accrue additional data relevant to safety and efficacy even after an EUA is submitted. The final estimates of vaccine efficacy for both primary and secondary endpoints will depend on the totality of data that will accumulate to inform the final analysis. Moderna worked closely with BARDA and the NIH, including NIAID’s COVID-19 Prevention Network (CoVPN), to conduct the Phase 3 COVE study under Operation Warp Speed. Moderna’s partner PPD (Nasdaq: PPD), a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services, has also been essential to the successful execution of the COVE study.

The Phase 3 COVE study was designed in collaboration with the FDA and NIH to evaluate Americans at risk of severe COVID-19 disease and completed enrollment of more than 30,000 participants ages 18 and older in the U.S. on October 22, including those at high risk of severe complications of COVID-19 disease. The COVE study includes more than 7,000 Americans over the age of 65. It also includes more than 5,000 Americans who are under the age of 65 but have high-risk chronic diseases that put them at increased risk of severe COVID-19, such as diabetes, severe obesity and cardiac disease. These medically high-risk groups represent 42% of the total participants in the Phase 3 COVE study. The study also included communities that have historically been under-represented in clinical research and have been disproportionately impacted by COVID-19. The study includes more than 11,000 participants from communities of color, representing 37% of the study population, which is similar to the diversity of the U.S. at large. This includes more than 6,000 participants who identify as Hispanic or LatinX, and more than 3,000 participants who identify as Black or African American.

#42

Re: Seguimiento de Moderna (MRNA)

SegúnTipRanks.com sobre el análisis de los últimos 3 meses de la cotización de Moderna Inc. una media de 13 analistas, concluyen un target objetvio de 180,18 $. Seis de ellos, recomiendan comprar, con un objetivo de 250 $, 5 analistas opinan mantener y su target en 180,18 $ y finalmente dos analistas sugieren vender y su target es de 121 $. La cotización de ayer fue de 146,81 $.
#43

Re: Seguimiento de Moderna (MRNA)

Que poco aguanta el personal. Ya están por encima del 300% en el último año
#44

Re: Seguimiento de Moderna (MRNA)

 Impresionante, +7%, se come los 300 dólares 
#45

Re: Seguimiento de Moderna (MRNA)

Otro tirón, +8%